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Abstract
Background: Expanded carrier screening (ECS) utilizes high-
throughput next-
generation sequencing to evaluate an individual's carrier status for multiple conditions. Combined malonic and methylmalonic aciduria (CMAMMA) due to ACSF3
deficiency is a rare inherited disease included in such screening panels. Some cases
have been reported with metabolic symptoms in childhood yet other cases describe a
benign clinical course, suggesting the clinical phenotype is not well defined.
Methods/Case Report: Clinical and laboratory findings during the prenatal period
were obtained retrospectively from medical records.
Results: A 37-year-old nulliparous woman and her partner were each identified as
carriers of ACSF3 variants and presented at 9 weeks gestation for prenatal genetic
consultation. The couple received extensive genetic counseling and proceeded with
chorionic villus sampling at 11 weeks gestation. Subsequent analysis confirmed that
the fetus inherited both parental ACSF variants. The couple was devastated by the
results and after reviewing options of pregnancy continuation and termination, they
decided to terminate the pregnancy. Following this decision, the patient was diagnosed with acute stress disorder.
Conclusion: This case highlights how expanded carrier screening adds complexity to
reproductive decision-making. Stronger guidelines and additional research are needed
to direct and evaluate the timing, composition, and implementation of ECS panels.
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IN T RO D U C T IO N

Combined malonic and methylmalonic aciduria, or
CMAMMA, is a rare disease for which the ACSF3 gene
(OMIM #614265) was recently identified by exome sequencing as the most common underlying genetic cause (Alfares
et al., 2011; Sloan et al., 2011). The ACSF3 gene encodes a
mitochondrial malonyl-and methylmalonyl-CoA synthetase,

which acylates malonic and methylmalonic acid to their
CoA derivatives for further use in mitochondrial metabolism
(Bowman & Wolfgang, 2019). The clinical phenotype of
this recently described condition is variable, and the natural
history remains to be fully defined. Although some reports
describe severe symptoms and signs, including metabolic acidosis, developmental delay, gastrointestinal disease, failure
to thrive, seizures, cardiomyopathy, and dysmorphic facial
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features, others document a benign clinical course in affected
adults and children (Alfares et al., 2011; Sloan et al., 2011).
In this report, we describe a couple referred for reproductive
genetic counseling, each identified as carriers of ACSF3 variants through expanded carrier screening, and discuss how the
genetic results affected their reproductive decision-making.
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CA S E

A 37-year-old G2P0010 woman and her partner presented
for reproductive genetic counseling at 9w2d gestation. Prior
to the visit, the patient and her partner had pursued fertility treatment and had undergone expanded genetic carrier
screening as part of their preconception evaluation, where
they were identified as carriers of ACSF3. The patient was
heterozygous for the pathogenic c.1672C>T (p.R558W)
variant, while her partner was found to carry the likely pathogenic variant c.1608G>A (p.W536X). They were in the
process of seeking preimplantation genetic testing for this
condition when they spontaneously conceived the current
pregnancy. They subsequently presented to reproductive genetic counseling to discuss options for prenatal genetic diagnosis. The couple was counseled on the broad spectrum of
the phenotype and the possibility of the fetus being clinically
unaffected despite inheriting both parental variants. The couple proceeded with chorionic villus sampling (CVS) that was
performed at 11w5d gestation. Direct-targeted analysis of
the parental variants confirmed that the fetus inherited both
parental ACSF3 variants. The couple was devastated by the
results and after reviewing options of pregnancy continuation
and termination, they decided to terminate the pregnancy.
Following this decision, the patient was diagnosed with acute
stress disorder.
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Ethical compliance

IRB approval from Thomas Jefferson University is not required for case report publications. Consent has been obtained from the patient.
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Genetic information

The GenBank version number for ACSF3 has the NCBI
Reference Sequence: NG_031961.1. The c.1672C>T
(p.R558W) variant discussed in this case has been reported
in the Ensembl database as a mutation in exon 11 of the gene,
transcript: ENST00000317447. The c.1608G>A (p.W536X)
variant discussed in this case has been reported in the
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Ensembl database as a mutation in exon 10 of the gene, transcript: ENST00000317447.
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DISCUSSION

Reproductive carrier screening is an important component of
preconception and prenatal care, and seeks to identify couples
at risk for conceiving a child with a particular genetic condition. Carrier screening began in the 1970s with the discovery
of the biochemical cause of Tay-Sachs disease (Wapner &
Biggio, 2019). Programs aimed at identifying carriers of this
disease in the Jewish community helped to significantly decrease the incidence of this severe and devastating disorder,
and in turn, became the model for community and ethnic-
based screening programs. Expanded carrier screening
(ECS) utilizes high-throughput next-generation sequencing
to evaluate an individual's carrier status for multiple conditions. ACOG Committee Opinion #690 states that “expanded
carrier screening is an acceptable screening strategy for preconception and prenatal carrier screening that must be tied to
appropriate counseling in a shared decision-making process
between physician and patient (ACOG, 2017).” Additional
considerations for carrier screening include prevalence of the
condition, carrier frequency of mutant alleles, detection rates,
age of onset, condition severity and residual risk (Edwards
et al., 2015). In 2009, the advent of next-generation sequencing enabled the identification of multiple disorders without
regard for the considerations delineated in current screening
guidelines, and has resulted in expanded carrier screening
(Haque et al., 2016).
Although the goal of ECS is to inform reproductive
decision-making, the rapid expansion of commercial laboratory genetic testing, fueled by corporate competition, has
extended the scope of the panel to include disorders beyond
those specified in recommended screening guidelines. At
this time, there are currently no specific guidelines regarding which disorders should be included on ECS panels. Per
the American College of Obstetricians and Gynecologists
(ACOG), ECS should meet several of the following criteria: (a) a carrier frequency of 1 in 100 or greater; (b) a well-
defined phenotype; (c) a detrimental effect on quality of life;
(d) causes cognitive or physical impairment; (e) requires surgical or medical intervention; or (f) has onset early in life.
The American College of Genetics and Genomics (ACMG)
adopts a similar stance; however, ACMG’s criteria provide
more structured guidance. For example, ACMG agrees that a
condition should have a well-defined phenotype. ACMG also
asserts that in cases of variable expressivity, incomplete penetrance, and for disorders associated with a mild phenotype,
inclusion of such disorders on screening panels should be
optional and transparent to facilitate reproductive decision-
making (Grody et al., 2013). The aforementioned criteria

GABRIEL et al.

from these two well-established professional organizations
serve practitioners with guidelines to determine which conditions should be included on ECS; however, neither set of
guidelines recommends specific disorders to be tested. The
criteria are vague and leave room for interpretation, especially those set forth by ACOG. At this time, the content of
ECS panels has been dictated by commercial laboratories,
and there is significant variation in gene/disease content between panels. In a study comparing 16 ECS providers, the
range of recessive disorders screened for was found to be 41 –
1792 and the number of genes ranged from 40 to 1556. More
striking, is that of the genes screened for by these panels
only three genes were screened by all 16 panels (Chokoshvili
et al., 2018). Due to ambiguity in the guidelines set forth by
ACOG and ACMG, commercial laboratories are able to offer
larger multi-gene panels, often at the same price as a smaller
panel of genes. Although patients may instinctively be drawn
to larger expanded carrier screening panels, they are often
unaware of the implications of positive results, and thus
unable to contextualize the importance of genetic testing.
Although ACOG and ACMG provide criteria that should be
met for inclusion on an expanded carrier screening panel, we
suggest forming a task force to create a list of recommended
genes for an expanded carrier screening panel based on these
criteria. A similar list was developed by ACMG for genes
associated with adult-onset medically actionable conditions.
This list of 59 genes provides guidance for reporting the
appropriate secondary findings on whole genome or whole
exome sequencing.
The couple we present faced a 25% risk of having a fetus
with CMAMMA and utilized diagnostic testing to confirm
the fetus inherited both pathogenic variants. Neither the parents nor their healthcare advocates were able to qualify how
CMAMMA would manifest, given the variability in clinical
phenotype. Thus, even though ECS informed this couple's
reproductive decision-making, it led them to more questions
and uncertainty. As a result, practitioners and patients are left
to determine whether “bigger” is actually “better” when deciding which panel to select, especially since cost tends not to
vary much with the size of the panel.
CMAMMA due to ACSF3 deficiency is a condition that,
despite having specific biochemical manifestations, lacks a
well-defined clinical phenotype. In some reported cases of
CMAMMA, the disease has a detrimental effect on the quality of life; however, in others, the disease presents with a clinically benign course. It may or may not cause cognitive or
physical impairment, and it may or may not require medical
intervention. Finally, the disease may present in children or
adults. Thus, in some cases of CMAMMA, the disease meets
the ACOG criteria for inclusion on an ECS panel and in other
cases, it meets none (Sloane et al., 2011).
Approximately 4 hours over the course of three different
Maternal-Fetal Medicine Genetics appointments were spent
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counseling this couple. Although the couple understood that
the fetus could be clinically asymptomatic despite inheriting
two pathogenic variants, they ultimately decided to terminate
the pregnancy. This decision later had a significant influence
on the patient's emotional and psychological state, to the point
where she was diagnosed with acute stress disorder. This
case demonstrates the need to evaluate the impact of ECS on
patients and healthcare organizations, while paying special
attention to the components of carrier screening panels, the
extra demands on genetic and reproductive counseling, the
burden of cost, and the patient's emotional and psychological
well-being (Wapner & Biggio, 2019).
Beyond consideration of how to implement the suggested
criteria for inclusion of disorders on ECS panels and the
counseling required by use of such panels, it is important
to consider the impact of the information attained by ECS
panels. Guo and Gregg (2019) used population data to estimate gene carrier rates of pathogenic and likely pathogenic
variants associated with a severe recessive condition. They
then simulated hypothetical ECS panels and discovered that
although gene carrier rates are high for any panel of genes,
the proportion of at-
risk couples is comparatively much
lower. They posit that when considering what to include on
a screening panel, three main costs should be considered:
(a) technical cost; (b) cost of interpretation and counseling;
(c) and cost of anxiety to the patient. In a joint statement of
the American College of Medical Genetics and Genomics,
American College of Obstetricians and Gynecologists,
National Society of Genetic Counselors, Perinatal Quality
Foundation, and Society for Maternal-Fetal Medicine, further research on the following areas is suggested for optimal
implementation of expanded carrier screening: curated data
repository of variants and phenotypes, education of healthcare providers and patients, educational resources for providers and patients, evaluation of patient and provider attitudes
toward ECS, and cost of ECS (Grody et al., 2013). While the
discussion regarding recommendations and considerations
for ECS continues, more specific guidance on what to include
on these panels is needed. The ambiguity allows companies
offering ECS to disregard this discussion and compete in the
marketplace using the number of genes on their panels as a
selling point (Edwards et al., 2015). Clinicians lack the appropriate resources to counsel patients on the wide variety of
disorders included in ECS and are often attempting to counsel patients after the results become available. Caution must
be exercised as ECS continues to participate in preconception
and prenatal decision-making, and more specific guidance is
needed to evaluate the timing, composition, and implementation of ECS panels. Thorough pre-test counseling is strongly
recommended prior to ordering expanded carrier screening
for a patient. Patients should be informed that the clinical
spectrum of some disorders on the test's panel is poorly understood; however, our knowledge of these conditions will
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likely improve over time as expanded carrier screening becomes more commonplace and more data become available.
In particular disorders where the phenotype is variable as in
CMAMMA, we suggest natural history studies be performed
to guide inclusion or exclusion on ECS. Expanded carrier
screening empowers patients with knowledge of their carrier
status; yet, it can also leave patients and healthcare providers
struggling to apply and understand this knowledge and how it
pertains to pregnancy.
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